These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28166651)

  • 1. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
    Rahman MM; Scalese MJ; Hansen RA
    Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
    Noguchi Y; Esaki H; Murayama A; Sugioka M; Koyama A; Tachi T; Teramachi H
    Eur J Clin Pharmacol; 2020 Feb; 76(2):299-304. PubMed ID: 31822955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
    Ohyama K; Okamoto T; Hori Y
    Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
    Béné J; Moulis G; Bennani I; Auffret M; Coupe P; Babai S; Hillaire-Buys D; Micallef J; Gautier S;
    Br J Dermatol; 2016 Aug; 175(2):296-301. PubMed ID: 27031194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
    Kinoshita S; Hosomi K; Yokoyama S; Takada M
    Int J Med Sci; 2020; 17(3):302-309. PubMed ID: 32132864
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
    Suzuki Y; Suzuki H; Umetsu R; Uranishi H; Abe J; Nishibata Y; Sekiya Y; Miyamura N; Hara H; Tsuchiya T; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(5):680-6. PubMed ID: 25947914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
    Huang J; Jia Y; Sun S; Meng L
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    Fahmy AI; Mekkawy MA; Abou-Ali A
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):175-181. PubMed ID: 30738497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
    Nagel AK; Ahmed-Sarwar N; Werner PM; Cipriano GC; Van Manen RP; Brown JE
    Ann Pharmacother; 2016 Jan; 50(1):27-31. PubMed ID: 26497885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System.
    Ogura T; Shiraishi C
    Clin Drug Investig; 2023 Feb; 43(2):129-140. PubMed ID: 36637688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
    Yi H; Lee JH; Shin JY
    Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
    Tamura T; Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2012; 9(6):441-6. PubMed ID: 22859904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
    Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.